Changjiang Pharmaceutical Group Management

Management criteria checks 1/4

We currently do not have sufficient information about the CEO.

Key information

Ming Luo

Chief executive officer

CN¥732.0k

Total compensation

CEO salary percentage	n/a
CEO tenure	1.9yrs
CEO ownership	n/a
Management average tenure	no data
Board average tenure	1.9yrs

Recent management updates

Recent updates

Changjiang Pharmaceutical Group Co., Ltd. (SZSE:300391) Looks Inexpensive After Falling 38% But Perhaps Not Attractive Enough

Apr 17

Changjiang Pharmaceutical Group Co., Ltd. (SZSE:300391) Not Doing Enough For Some Investors As Its Shares Slump 25%

Feb 27

CEO

Ming Luo (46 yo)

1.9yrs

Tenure

CN¥732,000

Compensation

Mr. Ming Luo is Non-Independent Director of Changjiang Pharmaceutical Group Co., Ltd. (formerly known as Kangyue Technology Co., Ltd.) from June 22, 2022. Mr. Luo is the General Manager of Changjiang Pharm...

Board Members

Name	Position	Tenure	Compensation	Ownership
Ming Luo	GM & Director	1.9yrs	CN¥732.00k	no data
Luhong Ning	Director	1.9yrs	CN¥350.00k	no data
Xuan Li	Non-Independent Director	4.2yrs	CN¥53.30k	no data
Lan Zhang	Non-Independent Director	1.9yrs	CN¥165.70k	no data
Qingkai Han	Non-Independent Director	1.9yrs	CN¥53.30k	no data
Yuanjun Deng	Independent Director	1.9yrs	CN¥53.30k	no data
Kangbing Wu	Independent Director	1.9yrs	CN¥53.30k	no data
Xia Lan	Independent Director	1.9yrs	CN¥53.30k	no data
Yuli Wang	Supervisor	1.9yrs	no data	no data
Xian Li	Chairman of the Supervisory Board	1.9yrs	no data	no data
Yong Xu	Supervisor	3.2yrs	no data	no data

1.9yrs

Average Tenure

45yo

Average Age

Experienced Board: 300391's board of directors are not considered experienced ( 1.9 years average tenure), which suggests a new board.

Changjiang Pharmaceutical Group Management

Management criteria checks 1/4

Key information

Recent management updates

Changjiang Pharmaceutical Group Co., Ltd., Annual General Meeting, May 21, 2024

High number of new and inexperienced directors

High number of new and inexperienced directors

Kangyue Technology Co., Ltd. Announces Board Appointments

High number of new directors

Recent updates

New major risk - Financial position

Changjiang Pharmaceutical Group Co., Ltd., Annual General Meeting, May 21, 2024

Changjiang Pharmaceutical Group Co., Ltd. (SZSE:300391) Looks Inexpensive After Falling 38% But Perhaps Not Attractive Enough

Changjiang Pharmaceutical Group Co., Ltd. to Report Q1, 2024 Results on Apr 26, 2024

Changjiang Pharmaceutical Group Co., Ltd. (SZSE:300391) Not Doing Enough For Some Investors As Its Shares Slump 25%

New minor risk - Share price stability

Changjiang Pharmaceutical Group Co., Ltd. to Report Fiscal Year 2023 Results on Apr 23, 2024

New minor risk - Share price stability

Third quarter 2023 earnings released: CN¥0.26 loss per share (vs CN¥0.19 profit in 3Q 2022)

Second quarter 2023 earnings released: CN¥0.004 loss per share (vs CN¥0.16 loss in 2Q 2022)

Changjiang Pharmaceutical Group Co., Ltd. to Report First Half, 2023 Results on Aug 23, 2023

Full year 2022 earnings released: CN¥0.066 loss per share (vs CN¥0.14 profit in FY 2021)

High number of new and inexperienced directors

Third quarter 2022 earnings released: EPS: CN¥0.19 (vs CN¥0.036 in 3Q 2021)

Second quarter 2022 earnings released: CN¥0.16 loss per share (vs CN¥0.07 profit in 2Q 2021)

High number of new and inexperienced directors

Kangyue Technology Co., Ltd. Announces Board Appointments

First quarter 2022 earnings: EPS misses analyst expectations

High number of new directors

Now 21% undervalued after recent price drop

Investor sentiment deteriorated over the past week

Third quarter 2021 earnings released: EPS CN¥0.036 (vs CN¥0.024 in 3Q 2020)

Investor sentiment deteriorated over the past week

Investor sentiment improved over the past week

Second quarter 2021 earnings released: EPS CN¥0.07 (vs CN¥0.007 loss in 2Q 2020)

Investor sentiment improved over the past week

Investor sentiment improved over the past week

First quarter 2021 earnings released: EPS CN¥0.17 (vs CN¥0.014 loss in 1Q 2020)

Kangyue Technology Co., Ltd. announced that it expects to receive CNY 140 million in funding

New 90-day low: CN¥9.48

New 90-day low: CN¥15.66

Third quarter earnings released

New 90-day high: CN¥20.01

New 90-day high: CN¥19.56

Kangyue Technology Co., Ltd. (SZSE:300391) intends to acquire 52.8% stake in Hubei Changjiangxing Pharmaceutical Co.,Ltd from Hubei Changjiang Pharmacy Chain Co., Ltd., Shenzhen Shengshi Fenghua Enterprise Management Co., Ltd. and Wang Dongxiang for approximately CNY 1.4 billion.

First half earnings released

New 90-day high - CN¥18.60

Kangyue Technology Co., Ltd. to Report First Half, 2020 Results on Aug 28, 2020

New 90-day high - CN¥15.14

Liu Lili completed the acquisition of a 5% stake in Kangyue Technology Co., Ltd. (SZSE:300391) from Beijing Wenming Investment Fund Management Co., Ltd.

CEO

Tenure

Compensation

Board Members

Average Tenure

Average Age